Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 121043734 | 12104373 | 4 | F | 20151217 | 20160824 | 20160223 | 20160905 | EXP | DE-ROCHE-1714389 | ROCHE | 81.00 | YR | F | Y | 69.00000 | KG | 20160905 | MD | DE | DE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 121043734 | 12104373 | 1 | PS | Ranibizumab | RANIBIZUMAB | 1 | Other | LEFT EYE | 180116R1A | 125156 | .5 | MG | SOLUTION FOR INJECTION | ||||||
| 121043734 | 12104373 | 2 | SS | Ranibizumab | RANIBIZUMAB | 1 | Other | LEFT EYE | 180116R1A | 125156 | .5 | MG | SOLUTION FOR INJECTION | ||||||
| 121043734 | 12104373 | 3 | SS | Ranibizumab | RANIBIZUMAB | 1 | Other | LEFT EYE | 180116R1A | 125156 | .5 | MG | SOLUTION FOR INJECTION | ||||||
| 121043734 | 12104373 | 4 | SS | Ranibizumab | RANIBIZUMAB | 1 | Other | LEFT EYE, ON 21/MAR/2016 | 180116R1A | 125156 | .5 | MG | SOLUTION FOR INJECTION | ||||||
| 121043734 | 12104373 | 5 | SS | Ranibizumab | RANIBIZUMAB | 1 | Other | 0.5 MG, RIGHT EYE | 180116R1A | 125156 | .5 | MG | SOLUTION FOR INJECTION | ||||||
| 121043734 | 12104373 | 6 | SS | Ranibizumab | RANIBIZUMAB | 1 | Other | 0.5 MG, LEFT EYE | 180116R1A | 125156 | .5 | MG | SOLUTION FOR INJECTION | ||||||
| 121043734 | 12104373 | 7 | SS | Ranibizumab | RANIBIZUMAB | 1 | Other | 0.5 MG, LEFT EYE | 180116R1A | 125156 | .5 | MG | SOLUTION FOR INJECTION | ||||||
| 121043734 | 12104373 | 8 | SS | Ranibizumab | RANIBIZUMAB | 1 | Intraocular | 0.5 MG, RIGHT EYE | 180116R1A | 125156 | .5 | MG | SOLUTION FOR INJECTION | ||||||
| 121043734 | 12104373 | 9 | C | INFLANEFRAN | 2 | Unknown | UNK | N | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 121043734 | 12104373 | 1 | Neovascular age-related macular degeneration |
| 121043734 | 12104373 | 9 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 121043734 | 12104373 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 121043734 | 12104373 | Cataract | |
| 121043734 | 12104373 | Concomitant disease aggravated | |
| 121043734 | 12104373 | Cystoid macular oedema | |
| 121043734 | 12104373 | Detachment of retinal pigment epithelium | |
| 121043734 | 12104373 | Dry age-related macular degeneration | |
| 121043734 | 12104373 | Metamorphopsia | |
| 121043734 | 12104373 | Neovascular age-related macular degeneration | |
| 121043734 | 12104373 | Retinal degeneration | |
| 121043734 | 12104373 | Subretinal fluid |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 121043734 | 12104373 | 1 | 20151109 | 0 | ||
| 121043734 | 12104373 | 2 | 20151214 | 20151214 | 0 | |
| 121043734 | 12104373 | 3 | 20160120 | 20160120 | 0 | |
| 121043734 | 12104373 | 4 | 20160321 | 0 | ||
| 121043734 | 12104373 | 5 | 20160428 | 0 | ||
| 121043734 | 12104373 | 6 | 20160428 | 0 | ||
| 121043734 | 12104373 | 7 | 20160609 | 20160609 | 0 | |
| 121043734 | 12104373 | 8 | 20160609 | 20160609 | 0 | |
| 121043734 | 12104373 | 9 | 20160609 | 20160714 | 0 |